Transcriptomic profiling of glia in Huntington's disease
dc.contributor.advisor
Williams, Anna
dc.contributor.advisor
Priller, Josef
dc.contributor.advisor
Seeker, Luise
dc.contributor.advisor
Lyons, David
dc.contributor.author
Bøstrand, Sunniva Marie Kjenstadbakk
dc.date.accessioned
2023-02-10T15:58:19Z
dc.date.available
2023-02-10T15:58:19Z
dc.date.issued
2023-02-10
dc.description.abstract
Huntington’s disease (HD) is a severely debilitating, autosomal dominant neurodegenerative
disease with a fatal outcome. There is accumulating evidence of a prominent
role of glia in the pathology of HD, and we investigated this by conducting
single nuclear RNA sequencing of human post mortem brain in 4 regions; caudate
nucleus, frontal cortex, hippocampus and cerebellum. Across 127,205 nuclei from
HD patients and age and sex matched controls, we found an altered heterogeneity
of glia in HD. We describe prominent changes in gene expression and abundance
of certain subtypes of astrocytes, microglia, oligodendrocyte precursor cells and oligodendrocytes
between HD and control samples, and these differences are widespread
across brain regions. Furthermore, we highlight two possible mechanisms
that characterise the glial contribution to disease pathology. Firstly, we show that
upregulation of molecular chaperones represents a cross-glial signature in HD, which
likely reflects an adaptive response to the aggregation of Huntingtin protein and might
promote cell survival. Secondly, we show an oligodendrocyte-specific upregulation of
the calmodulin-dependent 3’,5’-cyclic nucleotide phosphodiesterase 1A (PDE1A) in
HD compared to controls, which could cause dysfunction to key cellular functions
through its downregulation of the important second messengers cyclic adenosine
monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). Our results
support the hypothesis that glia have an independent role in the pathology of HD,
and we show that all types of glia are affected in the disease. As glia are selfrenewing
and therefore more tractable for treatment than neurons, our findings may
be of therapeutic relevance.
en
dc.identifier.uri
https://hdl.handle.net/1842/39835
dc.identifier.uri
http://dx.doi.org/10.7488/era/3083
dc.language.iso
en
en
dc.publisher
The University of Edinburgh
en
dc.subject
Transcriptomic Profiling
en
dc.subject
Huntington's Disease
en
dc.subject
Glia in Huntington's Disease
en
dc.subject
glia
en
dc.subject
cyclic adenosine monophosphate
en
dc.subject
cAMP
en
dc.subject
cyclic guanosine monophosphate
en
dc.subject
cGMP
en
dc.title
Transcriptomic profiling of glia in Huntington's disease
en
dc.type
Thesis or Dissertation
en
dc.type.qualificationlevel
Doctoral
en
dc.type.qualificationname
PhD Doctor of Philosophy
en
Files
Original bundle
1 - 1 of 1
- Name:
- BøstrandSMK_2023.pdf
- Size:
- 3.68 MB
- Format:
- Adobe Portable Document Format
- Description:
This item appears in the following Collection(s)

